A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.

Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Masaomi NangakuYasuhiro Komatsu

Abstract

Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in Japan for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open-label, single-arm study evaluated the efficacy and safety of vadadustat in 24 Japanese patients with CKD-associated anemia on hemodialysis who were not receiving erythropoiesis-stimulating agents (ESAs). Patients received vadadustat for 24 weeks; the starting dose was 300 mg/day and doses were adjusted to achieve the target hemoglobin (Hb) range of 10.0-12.0 g/dL. The least squares mean of average Hb at Weeks 20 and 24 (95% confidence interval) was 10.75 g/dL (10.35, 11.14). The most common adverse event was shunt stenosis (25.0%). Adverse drug reactions (diarrhea and vomiting) occurred in two patients (8.3%) and the severity was mild. Vadadustat increased and maintained Hb levels within the target range and was generally well-tolerated in Japanese patients with anemia on hemodialysis not receiving ESAs.

References

Oct 4, 2007·British Journal of Cancer·C KutA S Popel
Dec 16, 2011·Nature Reviews. Cancer·Brian KeithM Celeste Simon
Aug 7, 2012·Genes & Cancer·Bryan L KrockM Celeste Simon
Aug 28, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ioannis KoulouridisBertrand L Jaber
Jun 10, 2015·Nature Reviews. Nephrology·Mark J Koury, Volker H Haase
Jan 25, 2017·American Journal of Nephrology·Francesco LocatelliIain C Macdougall
Mar 28, 2017·American Journal of Nephrology·Edouard R MartinEmil M deGoma
Jul 26, 2017·Trends in Cancer·Luana Schito, Gregg L Semenza
Apr 20, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Volker H HaasePeter A McCullough
Nov 10, 2018·Current Molecular Medicine·Aldo Pezzuto, Elisabetta Carico
Jul 25, 2019·The New England Journal of Medicine·Nan ChenKin-Hung P Yu
Feb 6, 2020·Annals of Translational Medicine·Yu KurataMasaomi Nangaku
Jul 29, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Masaomi NangakuZeeshan Khawaja
Apr 23, 2021·Journal of the American Society of Nephrology : JASN·Masaomi NangakuYasuhiro Komatsu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Masaomi NangakuYasuhiro Komatsu
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Masaomi NangakuZeeshan Khawaja
© 2021 Meta ULC. All rights reserved